PMID: 42131512

Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis.

Ghosal Samit, Sinha Binayak

European heart journal open · 2026

Vol. 6, Issue 2, pp. oeag071

View on PubMedDOI

This entry links to third-party literature. For research use only.

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.